Shigella4V2

BIOLOGICAL2 trials

Sponsors

LimmaTech Biologics AG

Conditions

Shigellosis

Phase 2

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

CompletedNCT06523231

LimmaTech Biologics AGShigellosis

Start: 2025-04-07End: 2026-01-22Updated: 2026-02-09

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

RecruitingNCT06615375

LimmaTech Biologics AGShigellosis

Start: 2024-11-12End: 2026-09-01Target: 120Updated: 2026-02-09